featured
Improved Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-Up
JAMA Oncol 2020 May 29;[EPub Ahead of Print], H Joensuu, M Eriksson, K Sundby Hall, A Reichardt, B Hermes, J Schütte, S Cameron, P Hohenberger, PJ Jost, SE Al-Batran, LH Lindner, S Bauer, E Wardelmann, B Nilsson, R Kallio, P Jaakkola, J Junnila, T Alvegård, P ReichardtFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.